Defining the critical hurdles in cancer immunotherapy
Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific basis, others do not. We need to do better. Innovative strategies need to move i...
Similar Items
-
Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy
by: Parmiani, Giorgio, et al.
Published: (2015) -
The early antitumor immune response is necessary for tumor growth: Re-visiting Prehn’s hypothesis in the human melanoma system
by: Parmiani, Giorgio, et al.
Published: (2012) -
Genetics of inherited primary arrhythmia disorders
by: Spears, Danna A, et al.
Published: (2015) -
Toward the harmonization of immune monitoring in clinical trials: Quo vadis?
by: Britten, C. M., et al.
Published: (2007) -
Immune correlates of metastatic melanoma patients treated with ipilimumab in combination with fotemustine in the phase II NIBIT-M1 study
by: Maccalli, Cristina, et al.
Published: (2013)